Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression

Journal of Psychopharmacology

Volumn 27, Issue 10, 2013, Pages 915-920

  Tammiste, Anu ^a,b   Jiang, Tao ^c   Fischer, Krista ^b   Mägi, Reedik ^b   Krjutškov, Kaarel ^b,d,e   Pettai, Kristi ^b   Esko, Tõnu ^a,b   Li, Yingrui ^c   Tansey, Katherine E ^f   Carroll, Liam S ^f   Uher, Rudolf ^f,g   McGuffin, Peter ^f   Võsa, Urmo ^a   Tšernikova, Natalia ^a   Saria, Alois ^h   Ng, Pauline C ^b   Eller, Triin ^a   Vasar, Veiko ^a   Nutt, David J ⁱ   Maron, Eduard ^a,i   Wang, Jun ^a,j,k,l   Metspalu, Andres ^a,b   more..

^a UNIVERSITY OF TARTU   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

^c BGI SHENZHEN   (China)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Competence Centre of Reproductive Medicine and Biology ^*  (Estonia)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g DALHOUSIE UNIVERSITY   (Canada)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j Capital Region   (Denmark)

^k KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^l AARHUS UNIVERSITY   (Denmark)

more..

Author keywords

antidepressant; BMP5; exome sequencing; Major depression; pharmacogenomics; SSRI

Indexed keywords

BONE MORPHOGENETIC PROTEIN 5; ESCITALOPRAM;

ADULT; ALLELE; ARTICLE; BMP5 GENE; CONTROLLED STUDY; DEPRESSION; DRUG SAFETY; DRUG WITHDRAWAL; EXOME; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENETIC MARKER; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSANT; BMP5; EXOME SEQUENCING; MAJOR DEPRESSION; PHARMACOGENOMICS; SSRI;

ADULT; ALLELES; BONE MORPHOGENETIC PROTEIN 5; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; EXOME; FEMALE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84883876168     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113499829     Document Type: Article

References (24)

1. Beck HN, Drahushuk K, Jacoby DB, et al. Bone morphogenetic protein-5 (BMP-5) promotes dendritic growth in cultured sympathetic neurons. BMC Neurosci. 2001 ; 2: 12
2. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004 ; 429: 464-468
3. Furuta Y, Piston DW, Hogan BL. Bone morphogenetic proteins (BMPs) as regulators of dorsal forebrain development. Development. 1997 ; 124: 2203-2212
4. Garriock HA, Kraft JB, Shyn SI, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010 ; 67: 133-138
5. Holsboer F. How can we realize the promise of personalized antidepressant medicines?. Nat Rev Neurosci. 2008 ; 9: 638-646
6. Ising M, Lucae S, Binder EB, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009 ; 66: 966-975
7. Kato M, Serretti A. Review and meta-Analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010 ; 15: 473-500
8. Lein PJ, Beck HN, Chandrasekaran V, et al. Glia induce dendritic growth in cultured sympathetic neurons by modulating the balance between bone morphogenetic proteins (BMPs) and BMP antagonists. J Neurosci. 2002 ; 22: 10377-10387
9. Li R, Li Y, Fang X, et al. SNP detection for massively parallel whole-genome resequencing. Genome Res. 2009a ; 19: 1124-1132
10. Li R, Li Y, Kristiansen K, et al. SOAP: Short Oligonucleotide Alignment Program. Bioinformatics. 2008 ; 24: 713-714
11. Li R, Yu C, Li Y, et al. SOAP2: An improved ultrafast tool for short read alignment. Bioinformatics. 2009b ; 25: 1966-1967
12. Li Y, Vinckenbosch N, Tian G, et al. Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. Nat Genet. 2010 ; 42: 969-972
13. Maron E, Tammiste A, Kallassalu K, et al. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol. 2009 ; 19: 451-456
14. Mehler MF, Mabie PC, Zhang D, et al. Bone morphogenetic proteins in the nervous system. Trends Neurosci. 1997 ; 20: 309-317
15. Nutt DJ. Rationale for, barriers to, and appropriate medication for the long-term treatment of depression. J Clin Psychiatry. 2010 ; E1: e02
16. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007 ; 81: 559-575
17. Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet. 2011 ; 12: 683-691
18. Solloway MJ, Robertson EJ. Early embryonic lethality in Bmp5;Bmp7 double mutant mice suggests functional redundancy within the 60A subgroup. Development. 1999 ; 126: 1753-1768
19. Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry. 2010 ; 68: 536-543
20. Tilleman H, Hakim V, Novikov O, et al. Bmp5/7 in concert with the mid-hindbrain organizer control development of noradrenergic locus coeruleus neurons. Mol Cell Neurosci. 2010 ; 45: 1-11
21. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006 ; 354: 1243-1252
22. Uher R, Maier W, Hauser J, et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry. 2009 ; 194: 252-259
23. Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010 ; 167: 555-564
24. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 ; 21: 655-679